Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Kay-Dietrich Wagner
 -- 6082 2022-08-10 14:27:41 |
2 format
Jason Zhu
 -37 word(s) 6045 2022-08-11 04:26:58 | |
3 format
Jason Zhu
 -6 word(s) 6039 2022-08-12 04:50:46 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Wagner, N.;  Wagner, K. PPARs and the Hallmarks of Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/26040 (accessed on 27 December 2024).
Wagner N,  Wagner K. PPARs and the Hallmarks of Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/26040. Accessed December 27, 2024.
Wagner, Nicole, Kay-Dietrich Wagner. "PPARs and the Hallmarks of Cancer" Encyclopedia, https://encyclopedia.pub/entry/26040 (accessed December 27, 2024).
Wagner, N., & Wagner, K. (2022, August 10). PPARs and the Hallmarks of Cancer. In Encyclopedia. https://encyclopedia.pub/entry/26040
Wagner, Nicole and Kay-Dietrich Wagner. "PPARs and the Hallmarks of Cancer." Encyclopedia. Web. 10 August, 2022.
PPARs and the Hallmarks of Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cells11152432

Peroxisome proliferator-activated receptors (PPARs) function as nuclear transcription factors upon the binding of physiological or pharmacological ligands and heterodimerization with retinoic X receptors. Physiological ligands include fatty acids and fatty-acid-derived compounds with low specificity for the different PPAR subtypes (alpha, beta/delta, and gamma). For each of the PPAR subtypes, specific pharmacological agonists and antagonists, as well as pan-agonists, are available. In agreement with their natural ligands, PPARs are mainly focused on as targets for the treatment of metabolic syndrome and its associated complications. Nevertheless, many publications are available that implicate PPARs in malignancies. In several instances, they are controversial for very similar models.

PPAR cell proliferation angiogenesis cellular metabolism immune surveillance

1. Introduction

In addition to receptors for steroid and thyroid hormones, vitamin D and retinoids, and several orphan receptors, peroxisome proliferator-activated receptors (PPARs) belong to the group of nuclear receptors [1][2]. Although peroxisome proliferation in response to hypolipidemic fibrate drugs (PPAR alpha agonist) was described already in 1970s [3][4], it took nearly 20 years for PPAR alpha (PPARα), PPAR beta/delta (PPARβ/δ), and PPAR gamma (PPARγ) to be identified [5][6][7]. On the molecular level, PPARs activate/repress target genes as heterodimers with retinoic X receptors (RxR), which exist in three different isoforms. Liver X receptor α (LxRα) and retinoic acid receptors (RAR)s also form heterodimers with RxR. Thus, depending on the level of expression of the different receptors, the outcome of PPAR activation might differ between cell types [1]. In addition to the classical PPAR/RxR transcriptional complexes [8], PPARs might also interact with glucocorticoid receptors, photoreceptor-specific nuclear receptors, and estrogen-related receptors, which could additionally modify the responses of PPAR activation [9]. As a general PPAR response element, a direct repeat of the sequence AGGTCA, spaced by a single nucleotide, has been originally identified (DR1); in fact for PPAR alpha only [10]. Binding exclusively to this element would not explain the specificity of the identified PPAR alpha, beta/delta, and gamma target genes. Furthermore, thousands of these elements are found in the genome, mostly far away from the gene promoter regions. Experimental evidence suggests a higher heterogeneity of binding elements for PPARs [1][11]. The ligand-dependent and ligand-independent effects, posttranscriptional modifications, co-activators, and co-repressors of PPARs have been extensively researched [1][12][13].
Endogenous ligands for PPARs include unsaturated fatty acids, eicosanoids, prostaglandins, and prostacyclins [1][14]. Synthetic activators and inhibitors for all PPARs are available. Until now, only PPARα agonists (e.g., fibrates) have been in clinical use for lipid lowering, the prevention of atherosclerosis, and cardiovascular disease [15][16], while PPARγ agonists (e.g., thiazolidinediones) lower glucose by increasing insulin sensitivity, mainly in skeletal muscle and adipose tissue [17]. In addition to these “classical” applications for the treatment of metabolism-related diseases and metabolic syndrome, PPARs might be involved in a variety of diseases [18] and PPAR modulators might become interesting candidates for neurodegenerative disorders [19], addiction [20], psychiatric disorders [21][22], hepatic and kidney diseases [12][23][24][25], and autoimmune and inflammatory diseases [16][26][27][28][29]. Importantly, PPARs are also critically involved in cancer. The expression of PPARs has been detected in various cancer types and cancer cell lines, but PPARs also play important roles in the tumor stroma, i.e., cancer-associated fibroblasts, mesenchymal cells, endothelial cells, and macrophages [30]. In addition to cancer cell growth, angiogenesis, and the antitumor immune response play an important role in cancer progression and metastasis [31].

2. PPARs and Cell Proliferation

2.1. PPARα

PPARα expression has been demonstrated in human breast cancer cell lines, which showed increased proliferation upon PPARα activation [32]. Leptin and glucose treatment stimulated breast cancer proliferation, which was accompanied by an upregulation of PPARα, suggesting the involvement of PPARα in this process [33]. Similarly, arachidonic acid (AA) has been found to promote breast cancer cell proliferation through the activation of PPARα [34]. However, contrasting results were obtained by another group [35]. The PPAR agonist fenofibrate reduced the proliferation of triple-negative breast cancer cells [36]. Similar results were obtained with clofibrate in inflammatory breast cancer cell lines [37]. Different outcomes on breast cancer cell proliferation may be explained by the different types of breast cancer cell lines used, but also by the different concentrations of fibrates. Tauber and colleagues reported stimulation of the proliferation of MCF-7 breast cancer cells with low fibrate concentrations, and suppression with high doses [38]. Dose-dependent effects of fibrates on cell proliferation have also been reported for human liver cancer cells [39]. The sustained activation of PPARα leads to liver tumorigenesis in rodents. However, in a PPARα humanized model, sustained PPARα activation very rarely provoked liver cancers, which suggests that structural differences between human and mouse PPARα are responsible for the differential susceptibility to peroxisome proliferator-induced hepatocarcinogenesis [40]. In an excellent study, Tanaka and colleagues provided evidence that the hepatitis C virus (HCV) core protein induces heterogeneous activation of PPARα in transgenic mice. The stabilization of PPARα through interaction with the Hepatitis C virus (HCV) core protein and an increase in non-esterified fatty acids, serving as endogenous PPARα ligands, were suggested to contribute to the age-dependent and multicentric hepatocarcinogenesis mediated by the core protein [41]. Interestingly, the hepatocyte restricted the constitutive activation of the PPARα-induced proliferation of hepatocytes, but not carcinogenesis, indicating that the PPARα activation of other cell types than hepatocytes is responsible for the carcinogenic effect of PPARα activation [42]. The existence of an alternatively spliced transcript variant (PPARA-tr) in humans, but not in rodents, with a deficient ligand-binding domain that is unable to bind to peroxisome proliferator-responsive DNA elements (PPREs) could partially explain the species differences in hepatocarcinogenesis [43][44]. A later study suggested a higher susceptibility of PPARα-knockout mice to diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) [45]. However, Kaipainen and colleagues evidenced a tumor-suppressive phenotype in PPARα-deficient mice. The absence of PPARα switches tumor-associated inflammation into tumor-suppressive inflammatory infiltrates, which inhibit tumor angiogenesis and tumor progression independently of the cellular tumor type [46]. Later, PPARα deficiency was also proposed to impair regulatory T-cell functions, leading to the inhibition of melanoma growth [47]. These studies confirm the importance of the molecular properties of stromal host cells for cancer progression, which also explains the differential outcomes of analyses in pure in vitro studies, leading to potential false therapeutic deductions. The PPARα agonist fenofibrate, for example, decreased endometrial cancer cell proliferation in vitro but failed to improve outcomes in vivo [48]. Yokoyama and co-workers reported an inhibition of proliferation in ovarian cancer cell lines in vitro, as well as a reduction in ovarian cancer cell tumor growth in vivo via the activation of PPARα with clofibrate [49]. PPARα is expressed in medulloblastoma cells, and PPARα activation with fenofibrate inhibited cell proliferation in medulloblastoma cell lines [50]. Similar results were proposed using fenofibrate treatment in a glioblastoma cell line [51] and neuroblastoma cells [52]. However, the overexpression of PPARα in glioma stem cells (GSCs) has been observed. GSCs are responsible for tumor initiation, treatment resistance, and recurrence. The knockdown (KD) of PPARα reduced the proliferative and tumor-forming capacities of GSCs, and xenografts failed to establish viable intracranial tumors [53]. PPARα was found to induce carnitine palmitoyltransferase 1C (CPT1C) in a breast and a pancreatic cancer cell line, leading to the activation of cell proliferation [54]. Using syngenic implantation of B16 melanoma, LLC1 lung carcinoma, and SKOV-3 ovarian cancer xenograft models, the efficiency of the tumor growth-inhibiting properties of the PPARα antagonist NXT629 has been demonstrated [55]. Li and colleagues showed that the level of PPARα and its activity were increased in 4-(methylnitrosamino)-l-(3-pyridyl)-lbutanone (NNK)-induced mouse-lung tumors. An increase in PPARα occurred before the formation of lung tumors, indicating that the molecular changes play a role in lung carcinogenesis [56]. In contrast, in two lung cancer cell lines, fenofibrate reduced cell proliferation [57]. PPARα activation in vivo using Wy-14,643 or bezafibrate reduced non-small-cell lung cancer (NSCLC) growth through the inhibition of a proangiogenic epoxygenase. Epoxygenases oxidize arachidonic acid to epoxyeicosatrienoic acids (EET), pro-angiogenic lipids which support tumor growth [58]. Although PPARα activation by Wy-14,643 did not alter proliferation of cancer cell lines in vitro, it reduced tumorigenesis in vivo through the inhibition of angiogenesis [59]. The PPARα agonist fenofibrate has further been demonstrated to suppress B cell lymphoma in mice through the modulation of lipid metabolism. B cell tumors trigger systemic lipid mobilization from white adipose tissue to the liver and increase very-low-density lipoprotein (VLDL)/low-density lipoprotein (LDL) release from the liver to promote tumor growth. B cell lymphoma cells express extremely low levels of PPARα; therefore, fenofibrate did not increase lipid utilization in the tumors but enhanced the clearance of lipids and blocked hepatic lipid release, leading to reduced tumor growth [60]. Fenofibrate has also been proposed to suppress colon cancer cell proliferation in vitro and in in vivo xenograft models through epigenetic modifications involving the inhibition of DNA Methyltransferase 1 (DNMT1) [61]. To summarize, given the highly controversial results regarding the tumor-suppressing or -promoting effects of therapeutic PPARα modulation, especially activation, this intervention seems to be inadequate in the context of cancer. To the best of the knowledge, no clinical trials for the use of PPARα agonists in cancer therapy exist. One trial with the PPARα antagonist TPST-1120 as a monotherapy, and in combination with Nivolumab, Docetaxel or Cetuximab, in subjects with advanced cancers (NCT03829436) is ongoing.

2.2. PPARβ/δ

PPARβ/δ expression has been reported in a variety of cancer tissues and cell lines. The effects of PPARβ/δ on cell proliferation and tumor growth are highly controversial, and have been researched recently; summarizing tables are provided [62]. Many studies focused on colon cancer. The discrepancy between the observed effects of PPARβ/δ activation can only lead to the conclusion that any therapeutical use of PPARβ/δ modulation has to be avoided. Most studies report a colon cancer-enhancing effect of PPARβ/δ. Examination of PPARβ/δ in human multistage carcinogenesis of the colorectum revealed that its expression increased from normal mucosa to adenomatous polyps to colorectal cancer. The most elevated PPARβ/δ levels were observed in colon cancer cells with a highly malignant morphology [63]. PPARβ/δ expression in human colon cancer tissues was associated with poor prognosis and a higher metastatic risk [64]. An opposite report has been published for human and mouse colon cancer samples; however, no histomorphological detection analysis of PPARβ/δ has been performed to allow for the correlation of PPARβ/δ with expression in malignant cancer cells [65]. It has been demonstrated that PPARβ/δ mediates mitogenic vascular endothelial growth factor (VEGF) release in colon cancer [66][67][68], although one report also claimed that a loss of PPARβ/δ would enhance vascular endothelial growth factor (VEGF) release [69]. PPARβ/δ has been shown to promote [66][70][71][72][73][74][75] or to inhibit [69][76][77] colon cancer in vivo. In line with a pro-tumorigenic role, PPARβ/δ activation via a high-fat diet (HFD) or PPARβ/δ agonist treatment allowed stem and progenitor cells to initiate tumorigenesis in the setting of a loss of the adenomatous polyposis coli (APC) tumor-suppressor gene [78]. PPARβ/δ-mediated epithelial hyperproliferation, which increases the risk for gastric adenocarcinoma, was further found to be induced by Helicobacter pylori infection [79]. Regarding breast cancer, most studies suggest a pro-tumorigenic function of PPARβ/δ. Only two in vitro studies from the same group using the same breast cancer cell line suggest a reduction in cell proliferation upon PPARβ/δ activation [80][81]. The same group published two very similar studies, one using neuroblastoma cell lines, and the other testicular embryonal carcinoma cells, in which PPARβ/δ overexpression and/or activation had beneficial tumor-cell proliferation- or growth-inhibiting effects [82][83]. In contrast, by applying a variety of different molecular tools as either overexpression or knockout models, or conducting pharmacological activation or inhibition of PPARβ/δ, it has been shown, in vivo, that PPARβ/δ favors mammary tumorigenesis [84][85][86][87]. 3-phosphoinositide-dependent kinase-1 (DK1) favors these tumorigenic properties of PPARβ/δ in breast cancer [85][86]. Fatty-acid-binding protein 5 (FABP5), which shuttles ligands from the cytosol to PPARβ/δ, underlines the importance of endogenous PPARβ/δ ligands for cancer growth, as knockout of FABP5 was sufficient to reduce mammary tumorigenesis [88]. In line with this, FABP5 has been shown to convert the strong anticarcinogenic properties of retinoic acid (RA) into tumor-promoting functions as it delivers RA to the mitogenic and anti-apoptotic PPARβ/δ receptor [89]. Similar to the effects observed in mammary carcinomas, activation of the FABP5/PPARβ/δ pathway was shown to promote cell survival, proliferation, and anchorage-independent growth in prostate cancer cells [90]. The oncogenic redirection of transforming growth factor (TGF)-β1 signaling via the activation of PPARβ/δ was also identified to promote prostate cancer growth [91]. One study, however, suggested the inhibition of prostate cancer growth by PPARβ/δ through a noncanonical and ligand-independent pathway [92]. The activation of PPARβ/δ has been proposed to inhibit liver tumorigenesis in hepatitis B transgenic mice [93]; however, in different human hepatocellular carcinoma cell lines, the activation of PPARβ/δ enhanced the growth of these cancer cells through the activation of cyclooxygenase (COX)-2 [94]. PPARβ/δ activation has been shown to inhibit melanoma skin cancer cell proliferation through repression of the Wilms tumor suppressor (WT)1 [95], which favors human melanoma progression [96]. PPARβ/δ-knockout animals were more susceptible to skin carcinogenesis as their wildtype counterparts and PPARβ/δ agonists inhibited keratinocyte proliferation [97], as well as proliferation in a human squamous-cell carcinoma cell line [98]. In line with these finding, the researchers proposed a protective effect of PPARβ/δ activation, coupled with the inhibition of COX-2 activity, to increase the efficacy of chemoprevention in skin tumorigenesis [99][100]. However, a later report from this group showed that PPARβ/ δ is not involved in the suppression of skin carcinogenesis by non-steroidal anti-inflammatory drugs (NSAID) which inhibit COX-2 [101]. In contrast to an inhibitory function of PPARβ/ δ in the tumorigenesis of non-melanoma skin cancers, one study clearly evidenced the pro-tumorigenic role of PPARβ/δ involving the direct activation of proto-oncogene tyrosine-protein kinase Src, which promotes the development of ultraviolet (UV)-induced skin cancer in mice [102]. An elegant study focused on the importance of fibroblast PPARβ/ δ expression in non-melanoma skin tumorigenesis. Although the chemically induced skin tumors of animals with the conditional deletion of PPARβ/ δ in fibroblasts showed increased proliferation, the tumor burden was smaller and the tumor onset delayed; this indicates the role of fibroblast PPARβ/δ in epithelial–mesenchymal communication, which further influences tumor growth [103]. Regarding lung cancer, high expression of PPARβ/δ limited to cancer cells has been demonstrated in human cancer samples. In lung cancer cell lines, the activation of PPARβ/δ stimulated proliferation and inhibited apoptosis [104][105]. Nicotine increases PPARβ/δ expression in lung carcinoma cells, which contributes to increased proliferation [106]. In contrast, one study using the activation of PPARβ/δ in two lung cancer cell lines in vitro did not find differences for proliferation upon stimulation of PPARβ/δ [107]. In transgenic mice lacking one or both PPARβ/δ alleles, the growth of RAF-induced lung adenomas was decreased [108]. Although cell proliferation in mouse LLC1 lung cancer cells was decreased upon activation of PPARβ/δ, LLC1 tumor growth in vivo was enhanced in mice with conditional vascular overexpression of PPARβ/δ, underlining the importance of crosstalk between the tumor stroma and cancer cells for tumor growth [11]. One study reported that PPARβ/δ activation promoted apoptosis and reduced the tumor growth of nasopharyngeal carcinoma cells [109]. PPARβ/δ was found to be highly expressed in liposarcoma compared to benign lipoma, and PPARβ/δ activation increased liposarcoma cell proliferation, which was mediated via the direct transcriptional repression of leptin by PPARβ/δ [110]. Additionally, in thyroid tumors, PPARβ/δ was increased and correlated with the expression of the proliferation marker Ki67. PPARβ/δ activation increased the cell proliferation of thyroid cells [111]. PPARβ/δ was highly expressed in epithelial ovarian cancer cell lines and the inhibition of PPARβ/δ reduced their proliferation and tumor growth in vivo. Interestingly, aspirin, a NSAID that preferentially inhibits COX-1, compromised PPARβ/δ function and cell growth by inhibiting extracellular signal-regulated kinases 1/2 [112]. PPARβ/δ promoted the survival and proliferation of chronic lymphocytic leukemia cells [113] and changed the outcome of signaling from cytokines such as interferons (IFNs) [114]. A detailed table on the effects of PPARβ/δ on cell proliferation and tumor growth can be found in [62]. In conclusion, most studies identified PPARβ/δ as a tumor-promoting factor which increases cell proliferation and cancer growth. Although some studies report the inhibition of cancer cell proliferation upon PPARβ/δ activation, the therapeutic modulation of PPARβ/δ appears dangerous. Consequently, no cancer-related clinical trials are reported.

2.3. PPARγ

PPARγ expression is found in a variety of cancer tissues and cell lines. The activation of PPARγ by different agonists increased the frequency and size of colon tumors in C57BL/6J-APCMin/+ mice [115][116]. However, in human colon cancer cell lines, PPARγ inhibited tumor-cell proliferation [117][118][119][120]. Prostate cancers were found to overexpress PPARγ. The PPARγ agonist troglitazone inhibited the proliferation of PC-3 prostate cancer cells in vitro and in xenograft models in vivo [121], which was confirmed by others in later studies [122][123]. Similarly, growth inhibition via PPARγ activation has been described for liposarcoma [124], gastric cancer [125][126], bladder carcinoma [123][127], renal cell carcinoma [123], neuroblastoma [128][129], glioblastoma [130][131], melanoma [132][133][134][135], NSCLC [136][137], adrenocortical cancer [138][139], hepatocellular carcinoma [140], endometrial carcinoma [141], ovarian cancer [142][143], multiple myeloma [144], B cell lymphoma [145], mesothelioma [146], and esophageal squamous-cell carcinoma [147]. Most of these studies used cancer cell lines and PPARγ agonist treatment in vitro. Exciting results for therapeutic effects of PPARγ activation have been obtained in chronic myeloid leukemia (CML). With standard therapies, mainly tyrosine kinase inhibitors (TKIs), only 10% of patients achieve a complete molecular response/remission (CMR). This is mainly due to a pool of quiescent CML leukemia stem cells (LSCs), which are not completely eradicated by TKIs. Prost and colleagues demonstrated that thiazolidinediones target this pool of LSCs through the decreased transcription of signal transducer and activator of transcription (STAT) 5, leading to sustained CMR in a small group of patients [148]. A proof-of-concept study including 24 patients yielded positive outcomes with a combined therapy of pioglitazone and imatinib (TKI) [149]. A phase 2 trial is ongoing (EudraCT 2009-011675-79). PPARγ has been identified as a critical modifier in thyroid carcinogenesis using transgenic animals harboring a knock-in dominant-negative mutant thyroid hormone receptor beta (TRbetaPV/PV mouse), which spontaneously develop follicular thyroid carcinoma. TRbetaPV/PV mice were crossed with PPARγ +/− mice, and it was shown that thyroid carcinogenesis progressed faster in animals with PPARγ haplo-insufficiency. Reduced PPARγ led to the activation of the nuclear factor-kappaB signaling pathway, resulting in the repression of apoptosis. Furthermore, the treatment of TRbetaPV/PV mice with rosiglitazone delayed the progression of thyroid carcinogenesis by decreasing cell proliferation [150]. Wu and colleagues showed that the inhibition of PPARγ via the overexpression of dominant negative PPARγ (dnPPARγ) in the myeloid cell lineage provokes systemic inflammation and an increase in myeloid-derived suppressor cells (MDSC), which led to immunosuppression and the appearance of multiple cancers [151]. In breast cancer [152][153] and uterine leiomyomas [154], the growth-inhibiting effect of PPARγ activation was attributed to the inhibition of estrogen-receptor signaling. This seems to be partially mediated through the repression of leptin’s stimulatory effects on estrogen signaling by PPARγ [155]. However, later, it was shown that the PPARγ agonist prostaglandin 15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) inhibits the transcriptional activity of estrogen receptor alpha via PPARγ-independent covalent modification of its DNA-binding domain [156]. Methylene-substituted diindolylmethanes (C-DIMs) are PPARγ-activating agents. They reduce the proliferation of breast cancer cell lines. However, the decrease in cell growth was not inhibited by PPARγ antagonists, indicating that the observed effect might be PPARγ-independent [157]. An elegant study used transgenic mice prone to mammary-gland cancer crossed with mice expressing a constitutively active form of PPARγ in the mammary gland. The resulting PyV/VpPPARγ females developed tumors with accelerated kinetics. Even before reaching maturity at around 30 days of age, female mice displayed palpable tumor masses. These results indicate that once an initiating event has taken place, increased PPARγ signaling exacerbates mammary-gland tumor development [158]; this is similar to the observed situation of accelerated colon cancer formation in APCMin/+ mice treated with thiazolidinediones described before [115][116]. Avena and colleagues focused on the importance of the tumor stroma for cancer growth. They demonstrated that the overexpression of PPARγ in breast cancer cells reduced tumor growth in a xenograft model and demonstrated increased autophagy in the tumor cells. However, when breast cancer cells were co-injected with PPARγ-overexpressing fibroblasts, tumor growth was significantly increased. Stromal cells with overexpression of PPARγ displayed metabolic features of cancer-associated fibroblasts, with increased autophagy, glycolysis, and senescence; this supports a catabolic pro-inflammatory microenvironment that metabolically enhances cancer growth. The activation of an autophagic program, therefore, have pro- or antitumorigenic effects, depending on the cellular context [159]. The mammary secretory-epithelial-cell-specific knockout of PPARγ enhanced tumor growth in a 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer model [160]. A small clinical trial in patients with early-stage breast cancer did not evidence differences in breast tumor-cell proliferation upon treatment with rosiglitazone, administered between the time of diagnostic biopsy and definitive surgery [161]. PPARγ ligands did not prevent chemically or UV-induced skin tumors, although they significantly inhibited basal-level keratinocyte proliferation [162].
It is important to note that the anti-cancer effects of thiazolidinediones (rosiglitazone, pioglitazone, and troglitazone) might be independent of PPARγ activation, as it has been demonstrated that they are mediated by translation inhibition [163]. In osteosarcoma cell lines, troglitazone enhanced proliferation in one study [164], and inhibited proliferation in another [165]. Srivastava and colleagues demonstrated, in a lung cancer model, that treatment with the PPARγ agonist pioglitazone triggers a metabolic switch that inhibits pyruvate oxidation and reduces glutathione levels. These metabolic changes increase reactive oxygen species (ROS) levels, which leads to the rapid hypophosphorylation of the retinoblastoma protein (RB) and cell-cycle arrest [166]. In a very recent study, Musicant and colleagues demonstrated that the inhibition of PPARγ might be beneficial in mucoepidermoid carcinoma (MEC), a salivary-gland cancer that is driven primarily by a transcriptional coactivator fusion composed of cyclic AMP-regulated transcriptional coactivator 1 (CRTC1) and mastermind-like 2 (MAML2). The chimeric CRTC1/MAML2 (C1/M2) oncoprotein induces transcriptional activation of the non-canonical peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) splice variant PGC-1α4, which regulates PPARγ-mediated insulin-like growth factor (IGF) 1 expression. The inhibition of PPARγ by inverse agonists inhibits MEC cell proliferation and tumor growth in xenograft models [167]. Besides the clinical trials already mentioned, one trial (NCT00408434) of efatutazone in patients with advanced solid malignancies and no curative therapeutic options reported evidence of disease control [168]. In other clinical trials investigating the effects of efatutazone in combination with carboplatin/paclitazel in NSCLC (NCT01199055), or in combination with erlotinib (NCT01199068), partial responses were around 40%. However, in a clinical trial for liposarcoma (NCT02249949), efatutazone resulted in neither complete nor partial responses. The development of efatutazone has been discontinued. Clinical trials for pioglitazone in the treatment of leukoplakia in head and neck cancer (NCT00099021) resulted in partial responses of 70%, and in another trial for oral leukoplakia (NCT00951379), partial responses of 46% were achieved. Over twenty years ago, a very small clinical trial in three patients with liposarcoma treated with troglitazone already provided some evidence for adipocytic differentiation and decreased proliferation [169]. However, no results are available for later trials with a higher number of patients enrolled (NCT00003058 and NCT00004180). A table with detailed information regarding clinical trials using PPARγ agonists for cancer treatment is given in [170]. Although a large body of evidence suggests that PPARγ functions as a tumor suppressor, the role of PPARγ in tumorigenesis remains controversial. The predominant use of in vitro cell culture studies is limited in its elucidation of the biological relevance of PPARγ in cancer, as complex gene–gene and gene–environment interactions are not considered. It can be concluded that the role of PPARγ in cancer depends on the specific cancer type, the tumor stage, and the tumor environment, which implies that the therapeutical modulation of PPARγ must be considered with caution.

3. PPARs and Cell Death

3.1. PPARα

The PPARα activator fenofibrate has been shown to induce apoptosis in a human hepatocellular carcinoma cell line through an increase in reactive oxygen species (ROS) [171]. As another molecular mechanism of PPARα-dependent apoptosis, it has been proposed that PPARα serves as an E3 ubiquitin ligase to induce Bcl2 ubiquitination and degradation, leading to apoptosis [172]. Additionally in endometrial cancer [173], breast cancer [174], glioblastoma [175], colon cancer [61][176], ovarian cancer [49], medulloblastoma [50], neuroblastoma [52], pancreatic cancer [177], and NSCLC [178], the activation of PPARα induced apoptosis. These studies were mainly performed using a cancer cell line in in vitro assays. Conjugated linoleic acids induced apoptosis in a variety of human cancer cell lines, which was accompanied by a strong increase in PPARα [179]. The synergistic pro-apoptotic anticancer activity of clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) and docosahexaenoic acid (DHA) in human cancer cells has also been suggested to be mediated by PPARα signaling [180]. Zang and colleagues reported that the dual PPARα/γ agonist TZD18 provoked apoptosis in human leukemia, glioblastoma, and breast cancer cell lines through the induction of the endoplasmic reticulum stress response [181]. Later, the same observations were made in gastric cancer cell lines [182]. However, it is not clear if these actions were mediated through combined PPARα/γ signaling or solely through PPARα or PPARγ signaling. Crowe and colleagues evidenced that combined therapy using PPAR and RXR ligands for breast cancer treatment resulted in growth inhibition. This was due to apoptosis when PPARα ligands were used. In contrast, PPARγ agonists provoked decreased growth characterized by S-phase inhibition [174]. In mantle-cell lymphoma (MCL), a type of aggressive B cell non-Hodgkin’s lymphoma, which is frequently resistant to conventional chemotherapies, fenofibrate efficiently induced apoptosis through the downregulation of tumor necrosis factor (TNF) α. The addition of recombinant TNFα partially rescued fenofibrate-induced apoptosis, whereas the PPARα antagonist GW6471 did not affect the fenofibrate effects. Therefore, it might be possible that fenofibrate induced apoptosis through other mechanisms than the activation of PPARα [183]. In retinoblastoma cells, apoptosis was induced by fatty acid synthase, which led to the downregulation of PPARα; however, the relationship between these molecular events has not been investigated [184]. Similarly, in hepatic carcinoma cells, apoptosis was induced by the flavonoid quercetin, which downregulated PPARα expression [185]. The cause–effect relationship remains to be elucidated. Fenofibrate was found to induce apoptosis in triple-negative breast cancer cell lines, which involved the activation of the nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cell (NF-κB) pathways, as the effect could be almost totally blocked by an NF-κB-specific inhibitor. The induction of apoptosis by fenofibrate was, however, independent of PPARα expression status, as the PPARα antagonist GW6471 did not change apoptosis induction by fenofibrate [36]. In contrast, the induction of apoptosis in hepatocellular carcinoma cells via the overexpression of PPARα was dependent on NF-κB signaling, as PPARα was found to directly interact with IκBα (nuclear factor kappa-light-polypeptide-gene-enhancer in B-cells inhibitor alpha) [45]. In contrast to most studies suggesting a pro-apoptotic function of PPARα activation, Li and coworkers reported that the PPARα inhibitor MT886 induced apoptosis in hepatocarcinoma cell lines, and the agonist fenofibrate significantly increased proliferation, the expression of cell-cycle-related protein (CyclinD1, CDK2), and cell-proliferation-related proteins (PCNA) [39]. Similarly, Abu Aboud and colleagues demonstrated enhanced apoptosis in renal-cell carcinoma upon PPARα inhibition in vitro [186] and in vivo through a decrease in enhanced fatty-acid oxidation and oxidative phosphorylation, and further cancer-cell-specific glycolysis inhibition [187]. The induction of apoptosis via PPARα inhibition has also been described in head and neck paragangliomas (HNPGLs); in one case, the researchers described the inhibition of the PI3K/GSK3β/β-catenin signaling pathway as the underlying molecular mechanism [188]. In conclusion, most of the studies suggest that PPARα activation induces apoptosis in cancer cells. However, given that a substantial number of research works also propose the opposite, and advise the use of PPARα inhibition to provoke apoptosis in tumor cells, no clear recommendation for therapeutic PPARα modulation in cancer treatment can be postulated.

3.2. PPARβ/δ

The function of PPARβ/δ in cancer-cell death was researched in detail in [62]. Most studies support the cell-death-preventing role of PPARβ/δ in tumor cells. In 1999, it was already demonstrated that PPARβ/δ was overexpressed in colorectal cancers (CRC) with adenomatous polyposis coli (APC)/β-catenin mutations, leading to the prevention of apoptosis in colon cancer cells. NSAIDs could compensate for this defect by suppressing PPARβ/δ and promoting apoptosis [189]. Cyclooxygenase-derived prostaglandin E2 (PGE2), which is overexpressed in most CRCs, was further found to indirectly transactivate PPARβ/δ to inhibit colon cancer-cell apoptosis [190]. Interestingly, it has been demonstrated that fibroblasts isolated from the mucosa of hereditary non-polyposis colorectal cancer (HNPCC) patients produced 50 times more PGE2 than normal fibroblasts. Stromal overproduction of PGE2 in HNPCC patients is likely to prevent the apoptosis of neoplastic lesions through the activation of PPARβ/δ, thereby facilitating progression into a malignant state [191]. Studies using HCT116 colon cancer cells confirmed that treatment with the PPARβ/δ agonist GW501516 diminished serum-withdrawal-induced apoptosis, which was not the case in PPARβ/δ-deficient HCT116 cells; this indicates the specificity of the apoptosis-preventing effect for PPARβ/δ [70]. Other mechanisms for the PPARβ/δ-mediated prevention of apoptosis in colon cancer have been suggested, such as the activation of the 14-3-3ε protein [192], or survivin [193] expression by PPARβ/δ. In contrast to these studies, one report suggested a pro-apoptotic function of PPARβ/δ in colon carcinoma. GW0742 agonist treatment induced apoptosis in wildtype, but not in PPARβ/δ-knockout animals with chemically induced colon carcinoma. Apoptosis was quantified via TdT-mediated dUTP-biotin nick-end labeling (TUNEL) staining of colon sections and subsequent cell counting; however, as no images were provided, it is difficult to assume TUNEL-specific positivity for cancer cells [76]. A study from the same group using different human colon cancer cell lines treated with hydrogen peroxide to induce apoptosis, different concentrations of the PPARβ/δ agonist GW0742, and NSAIDs could not find evidence for a decrease in apoptosis upon PPARβ/δ activation [65]. Conjugated linoleic acids (CLAs) were found to reduce proliferation in different human cancer cell lines. In cancer cell lines in which the inhibition of cell proliferation was correlated with apoptosis induction, PPARβ/δ expression became strongly downregulated [179]. PPARβ/δ activation decreased human and mouse melanoma cell proliferation; however, no changes in apoptosis could be observed [95]. The activation of PPARβ/δ has been shown to inhibit cisplatin-induced apoptosis in human lung cancer cell lines [104], and the knockout of PPARβ/δ induced apoptosis in lung cancer cells [105]. In mouse LLC1 lung cancer cells, the modulation of PPARβ/δ activity did not influence apoptosis [11]. The inhibition of PPARβ/δ sensitized neuroblastoma cells to retinoic acid-induced cell death [194]. In contrast, in prostate cancer cell lines, ginsenoside Rh2- [195] and telmisartan- [196] induced apoptosis were hampered by the inhibition of PPARβ/δ. In line with a pro-apoptotic function of PPARβ/δ, enhanced apoptosis in a bladder carcinoma cell line [197] as well as in nasopharyngeal tumor cells [109] and liver cancer cells [198] was reported upon PPARβ/δ activation.

3.3. PPARγ

Over twenty years ago, Padilla and colleagues already described that 15d-PGJ2 that binds to PPARγ exerts cytotoxicity in malignant B-cell lymphoma via apoptosis induction. Additionally, thiazolidinedione PPARγ agonists negatively affected B-lineage cells, indicating a specific PPARγ function of counteracting the stimulatory effects of prostaglandin E2 (PGE2) [199][200]. Later, the inhibition of NFκB was shown to be the major mechanism of 15d-PGJ2-induced apoptosis in aggressive B-cell malignancies. These effects were mimicked by the proteasome inhibitor MG-132, but not by troglitazone, suggesting that 15d-PGJ2-induced apoptosis is independent of PPARγ [201]. In multiple myeloma, the overexpression of PPARγ induced apoptosis through the inhibition of Interleukin-6 production [144]. Similarly, in acute myeloid leukemia (AML), the forced expression of PPARγ regulated the induction of apoptosis via caspase-8 activation [202]. The activation of PPARγ by 15d-PGJ2 has also been demonstrated to inhibit tyrosine phosphorylation of epidermal growth factor receptors ErbB-2 and ErbB-3 in a breast cancer cell line, leading to a dramatic increase in apoptosis [152]. A later study, however, showed that while 15d-PGJ2 activates PPRE-mediated transcription, PPARγ is not required for 15d-PGJ2-induced apoptosis in breast cancer cells. As other possible mechanisms of apoptosis induction by 15d-PGJ2, the inhibition of NFκB-mediated survival pathways, the inhibition of transcriptional activation of COX-2, and the inhibition of the ubiquitin proteosome were proposed [203]. The PPARγ-independent induction of apoptosis by 15d-PGJ2 has also been demonstrated in prostate and bladder carcinoma cells [204]. Additionally, 15d-PGJ2 induced apoptosis in pancreatic cancer cells through the downregulation of human telomerase reverse transcriptase (hTERT) [205]. Thiazolidinediones sensitize breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) therapy by reducing cyclin D3 levels, but not other D-type cyclins [206]. Later, combined treatment with TRAIL and PPARγ ligands, especially 15d-PGJ2, was proposed to overcome chemoresistance in ovarian cancers for successful apoptosis induction [207]. The simultaneous activation of PPARγ and RXR has been suggested to promote apoptosis, implicating the upregulation of p53 in breast cancer cell lines [208]. NSAIDs, considered in cancer prevention due to their inhibitory effect on cyclooxygenases (COX), have recently been proposed to exert their antineoplastic activity through the activation of PPARγ, which induces proline dehydrogenase/proline oxidase (PRODH/POX)-dependent apoptosis in breast cancer cells [209]. In many other studies PPARγ agonists induced apoptosis in bladder cancer [210], gastric carcinoma [126][211], lung cancer [212], esophageal adenocarcinoma [213], pancreatic cancer [214], hepatocellular carcinoma [215], neuroblastoma [216], melanoma [134][135], glioblastoma [217], leukemia [218], leiomyoma [219], mesothelioma [146], and colon carcinoma [220]. Nevertheless, it is not always clear if apoptosis induction is mediated via PPARγ activation. In colon carcinoma, increased PPARβ/δ expression and/or activation of PPARβ/δ antagonized the ability of PPARγ to induce cell death. The activation of PPARγ was found to decrease survivin expression and increase caspase-3 activity, whereas the activation of PPARβ/δ counteracted these effects [193]. A highly interesting study investigated the role of PPARγ coactivator-1 alpha (PGC-1α) in the induction of apoptosis in human epithelial ovarian cancer cells. The overexpression of PGC-1α in human epithelial ovarian cancer cells induced cell apoptosis through the coordinated regulation of Bcl-2 and Bax expression. The suppression of PPARγ expression via siRNA or PPARγ antagonist treatment inhibited PGC-1α-induced apoptosis, suggesting that PPARγ is required for apoptosis induction by PGC-1α [204]. Alternative promoter and mRNA splicing give rise to several PPARγ mRNA and protein isoforms [221]. Kim and coworkers identified a novel splice variant of human PPARγ 1 (hPPAR γ1) that exhibits dominant-negative activity in human tumor-derived cell lines and investigated the function of a truncated splice variant of hPPARγ 1 (hPPARγ1(tr)) in lung cancer. The overexpression of hPPARγ1(tr) rendered cancer cells more resistant to chemotherapeutic drug- and chemical-induced cell death [222]. PPARγ mediated apoptosis induction by n-3 polyunsaturated fatty acids (n-3 PUFA) in a breast cancer cell line, which might explain the beneficial effects of diets enriched in n-3 PUFA [223]. Like the results described above for breast cancer, in colon cancer, the anti-apoptotic activity of the PPARγ agonist troglitazone was also found to be independent of PPARγ. Instead of apoptosis induction through PPARγ, the activation of early growth response-1 (Egr-1) transcription factor was identified as the underlying molecular mechanism [224]. This has also been described for the apoptotic action of C-DIMs, PPARγ agonists, which decreased colon cancer cell survival through the PPARγ-independent activation of early growth response protein (Egr) 1 [120]. In contrast, Telmisartan, an angiotensin II receptor blocker (ARB), was found to inhibit cancer cell proliferation and induce apoptosis through the activation of PPARγ [225][226][227]. In contrast to these pro-apoptotic actions of PPARγ agonists, the PPARγ agonist troglitazone increased cell proliferation and inhibited staurosporine-induced apoptosis in several osteosarcoma cell lines through Akt activation [164]. Later, studies from the Kilgore lab provided evidence that the unreflected therapeutical use of PPARγ ligands in patients predisposed to or already diagnosed with cancer, especially breast cancer, could be dangerous. They identified Myc-associated zinc finger protein (MAZ) as a transcriptional mediator of PPARγ1 expression. The down-regulation of PPARγ1 expression led to reduced cellular proliferation and the induction of apoptosis in breast cancer cells [228]. Interestingly, it has been demonstrated that PPARγ ligands can have distinct activities. One relates to the ability of ligands to act as canonical agonists of the nuclear receptor on peroxisome proliferator response elements, which leads to adipogenesis. The second relates to the allosteric inhibition of phosphorylation of the Ser273 residue of PPARγ. PPARγ is phosphorylated in response to DNA damage, and the inhibition of phosphorylation by novel noncanonical ligands can sensitize cancer cells to DNA-damaging agents. They might represent a safer approach in cancer therapies as the established canonical agonists, which are used less and less frequently due to reported severe side effects or contradictory therapeutical outcomes [229]. A good study by Schaefer and colleagues using hepatocellular carcinoma cells demonstrated that PPARγ antagonists prevented adhesion to the extracellular matrix followed by caspase-dependent apoptosis (anoikis). They found that PPARγ inhibitor T0070907 was significantly more efficient in causing cancer-cell death than the activators troglitazone and rosiglitazone, which had no effect on cell adhesion and caused cell death at much higher concentrations [230]. Later studies confirmed this mechanism of anoikis induction by PPARγ antagonists in squamous-cell carcinoma [171][231]. Some reports evidenced autophagy induction in cancer cells upon PPARγ activation [232][233][234]. Autophagy can either suppress or promote tumor growth [235], and deducing that the induction of autophagy in cancers via PPARγ modulation might be beneficial is, consequently, erroneous. The difficulty in categorizing PPARγ activation in cancer therapy as beneficial or disadvantageous is also well-illustrated in a study from Baron and colleagues, who investigated the effects of ciglitazone in two different colon cancer cell lines: HT29 and SW480 cells. Ciglitazone induced apoptosis in HT29 cells, but stimulated SW480 cell proliferation. The researchers concluded that the differential responses for growth regulation result from cell-specific protein synthesis and differences in protein regulation [236]. Based on the outcomes of all these studies, it is therefore impossible to recommend PPARγ modulation to induce cancer-cell death.

References

  1. Wagner, K.D.; Wagner, N. Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol. Ther. 2010, 125, 423–435.
  2. Miyachi, H. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors. Int. J. Mol. Sci. 2021, 22, 9223.
  3. Moody, D.E.; Reddy, J.K. Increase in hepatic carnitine acetyltransferase activity associated with peroxisomal (microbody) proliferation induced by the hypolipidemic drugs clofibrate, nafenopin, and methyl clofenapate. Res. Commun. Chem. Pathol. Pharmacol. 1974, 9, 501–510.
  4. De Duve, C. Evolution of the peroxisome. Ann. N. Y. Acad. Sci. 1969, 168, 369–381.
  5. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645–650.
  6. Göttlicher, M.; Widmark, E.; Li, Q.; Gustafsson, J.A. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 1992, 89, 4653–4657.
  7. Dreyer, C.; Krey, G.; Keller, H.; Givel, F.; Helftenbein, G.; Wahli, W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68, 879–887.
  8. Plutzky, J. The PPAR-RXR transcriptional complex in the vasculature: Energy in the balance. Circ. Res. 2011, 108, 1002–1016.
  9. De Bosscher, K.; Desmet, S.J.; Clarisse, D.; Estébanez-Perpiña, E.; Brunsveld, L. Nuclear receptor crosstalk—Defining the mechanisms for therapeutic innovation. Nat. Rev. Endocrinol. 2020, 16, 363–377.
  10. Palmer, C.N.; Hsu, M.H.; Griffin, H.J.; Johnson, E.F. Novel sequence determinants in peroxisome proliferator signaling. J. Biol. Chem. 1995, 270, 16114–16121.
  11. Wagner, K.D.; Du, S.; Martin, L.; Leccia, N.; Michiels, J.F.; Wagner, N. Vascular PPARβ/δ Promotes Tumor Angiogenesis and Progression. Cells 2019, 8, 1623.
  12. Fougerat, A.; Montagner, A.; Loiseau, N.; Guillou, H.; Wahli, W. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 2020, 9, 1638.
  13. Feige, J.N.; Auwerx, J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol. 2007, 17, 292–301.
  14. Grygiel-Górniak, B. Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications—A review. Nutr. J. 2014, 13, 17.
  15. Montaigne, D.; Butruille, L.; Staels, B. PPAR control of metabolism and cardiovascular functions. Nat. Rev. Cardiol. 2021, 18, 809–823.
  16. Wagner, K.D.; Wagner, N. PPARs and Myocardial Infarction. Int. J. Mol. Sci. 2020, 21, 9436.
  17. Marx, N.; Davies, M.J.; Grant, P.J.; Mathieu, C.; Petrie, J.R.; Cosentino, F.; Buse, J.B. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021, 9, 46–52.
  18. Wagner, N.; Wagner, K.D. The Role of PPARs in Disease. Cells 2020, 9, 2367.
  19. Sáez-Orellana, F.; Octave, J.N.; Pierrot, N. Alzheimer’s Disease, a Lipid Story: Involvement of Peroxisome Proliferator-Activated Receptor α. Cells 2020, 9, 1215.
  20. Matheson, J.; Le Foll, B. Therapeutic Potential of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Substance Use Disorders: A Synthesis of Preclinical and Human Evidence. Cells 2020, 9, 1996.
  21. Quiroga, C.; Barberena, J.J.; Alcaraz-Silva, J.; Machado, S.; Imperatori, C.; Yadollahpour, A.; Budde, H.; Yamamoto, T.; Telles-Correia, D.; Murillo-Rodríguez, E. The Role of Peroxisome Proliferator-Activated Receptor in Addiction: A Novel Drug Target. Curr. Top. Med. Chem. 2021, 21, 964–975.
  22. Elias, E.; Zhang, A.Y.; Manners, M.T. Novel Pharmacological Approaches to the Treatment of Depression. Life 2022, 12, 196.
  23. Luan, Z.L.; Zhang, C.; Ming, W.H.; Huang, Y.Z.; Guan, Y.F.; Zhang, X.Y. Nuclear receptors in renal health and disease. EBioMedicine 2022, 76, 103855.
  24. Mantovani, A.; Byrne, C.D.; Targher, G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review. Lancet Gastroenterol. Hepatol. 2022, 7, 367–378.
  25. Kökény, G.; Calvier, L.; Hansmann, G. PPARγ and TGFβ-Major Regulators of Metabolism, Inflammation, and Fibrosis in the Lungs and Kidneys. Int. J. Mol. Sci. 2021, 22, 10431.
  26. Liu, Y.; Wang, J.; Luo, S.; Zhan, Y.; Lu, Q. The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review. J. Autoimmun. 2020, 113, 102510.
  27. Toobian, D.; Ghosh, P.; Katkar, G.D. Parsing the Role of PPARs in Macrophage Processes. Front. Immunol. 2021, 12, 783780.
  28. Gerussi, A.; Lucà, M.; Cristoferi, L.; Ronca, V.; Mancuso, C.; Milani, C.; D’Amato, D.; O’Donnell, S.E.; Carbone, M.; Invernizzi, P. New Therapeutic Targets in Autoimmune Cholangiopathies. Front. Med. 2020, 7, 117.
  29. Rzemieniec, J.; Castiglioni, L.; Gelosa, P.; Muluhie, M.; Mercuriali, B.; Sironi, L. Nuclear Receptors in Myocardial and Cerebral Ischemia-Mechanisms of Action and Therapeutic Strategies. Int. J. Mol. Sci. 2021, 22, 12326.
  30. Cheng, H.S.; Yip, Y.S.; Lim, E.K.Y.; Wahli, W.; Tan, N.S. PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis. Cancers 2021, 13, 2153.
  31. Wagner, K.D.; Cherfils-Vicini, J.; Hosen, N.; Hohenstein, P.; Gilson, E.; Hastie, N.D.; Michiels, J.F.; Wagner, N. The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression. Nat. Commun. 2014, 5, 5852.
  32. Suchanek, K.M.; May, F.J.; Robinson, J.A.; Lee, W.J.; Holman, N.A.; Monteith, G.R.; Roberts-Thomson, S.J. Peroxisome proliferator-activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol. Carcinog. 2002, 34, 165–171.
  33. Okumura, M.; Yamamoto, M.; Sakuma, H.; Kojima, T.; Maruyama, T.; Jamali, M.; Cooper, D.R.; Yasuda, K. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: Reciprocal involvement of PKC-α and PPAR expression. Biochim. Biophys. Acta 2002, 1592, 107–116.
  34. Chang, N.W.; Wu, C.T.; Chen, D.R.; Yeh, C.Y.; Lin, C. High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. J. Nutr. Biochem. 2013, 24, 274–281.
  35. Bocca, C.; Bozzo, F.; Martinasso, G.; Canuto, R.A.; Miglietta, A. Involvement of PPARα in the growth inhibitory effect of arachidonic acid on breast cancer cells. Br. J. Nutr. 2008, 100, 739–750.
  36. Li, T.; Zhang, Q.; Zhang, J.; Yang, G.; Shao, Z.; Luo, J.; Fan, M.; Ni, C.; Wu, Z.; Hu, X. Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway. BMC Cancer 2014, 14, 96.
  37. Chandran, K.; Goswami, S.; Sharma-Walia, N. Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer. Oncotarget 2016, 7, 15577–15599.
  38. Tauber, Z.; Koleckova, M.; Cizkova, K. Peroxisome proliferator-activated receptor ɑ (PPARɑ)-cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER + PR + HER2− breast cancer. Med. Mol. Morphol. 2020, 53, 141–148.
  39. Li, B.; Jiang, H.Y.; Wang, Z.H.; Ma, Y.C.; Bao, Y.N.; Jin, Y. Effect of fenofibrate on proliferation of SMMC-7721 cells via regulating cell cycle. Hum. Exp. Toxicol. 2021, 40, 1208–1221.
  40. Morimura, K.; Cheung, C.; Ward, J.M.; Reddy, J.K.; Gonzalez, F.J. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 2006, 27, 1074–1080.
  41. Tanaka, N.; Moriya, K.; Kiyosawa, K.; Koike, K.; Aoyama, T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor α in transgenic mice: Implications for HCV-associated hepatocarcinogenesis. Int. J. Cancer 2008, 122, 124–131.
  42. Yang, Q.; Ito, S.; Gonzalez, F.J. Hepatocyte-restricted constitutive activation of PPARα induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis 2007, 28, 1171–1177.
  43. Gervois, P.; Torra, I.P.; Chinetti, G.; Grötzinger, T.; Dubois, G.; Fruchart, J.C.; Fruchart-Najib, J.; Leitersdorf, E.; Staels, B. A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity. Mol. Endocrinol. 1999, 13, 1535–1549.
  44. Thomas, M.; Bayha, C.; Klein, K.; Müller, S.; Weiss, T.S.; Schwab, M.; Zanger, U.M. The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARα-tr, autonomously regulates proliferative and pro-inflammatory genes. BMC Cancer 2015, 15, 488.
  45. Zhang, N.; Chu, E.S.; Zhang, J.; Li, X.; Liang, Q.; Chen, J.; Chen, M.; Teoh, N.; Farrell, G.; Sung, J.J.; et al. Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway. Oncotarget 2014, 5, 8330–8340.
  46. Kaipainen, A.; Kieran, M.W.; Huang, S.; Butterfield, C.; Bielenberg, D.; Mostoslavsky, G.; Mulligan, R.; Folkman, J.; Panigrahy, D. PPARα deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2007, 2, e260.
  47. Hichami, A.; Yessoufou, A.; Ghiringhelli, F.; Salvadori, F.; Moutairou, K.; Zwetyenga, N.; Khan, N.A. Peroxisome proliferator-activated receptor alpha deficiency impairs regulatory T cell functions: Possible application in the inhibition of melanoma tumor growth in mice. Biochimie 2016, 131, 1–10.
  48. Saidi, S.A.; Holland, C.M.; Charnock-Jones, D.S.; Smith, S.K. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol. Cancer 2006, 5, 13.
  49. Yokoyama, Y.; Xin, B.; Shigeto, T.; Umemoto, M.; Kasai-Sakamoto, A.; Futagami, M.; Tsuchida, S.; Al-Mulla, F.; Mizunuma, H. Clofibric acid, a peroxisome proliferator-activated receptor α ligand, inhibits growth of human ovarian cancer. Mol. Cancer Ther. 2007, 6, 1379–1386.
  50. Urbanska, K.; Pannizzo, P.; Grabacka, M.; Croul, S.; Del Valle, L.; Khalili, K.; Reiss, K. Activation of PPARα inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int. J. Cancer 2008, 123, 1015–1024.
  51. Han, D.F.; Zhang, J.X.; Wei, W.J.; Tao, T.; Hu, Q.; Wang, Y.Y.; Wang, X.F.; Liu, N.; You, Y.P. Fenofibrate induces G0/G1 phase arrest by modulating the PPARα/FoxO1/p27 kip pathway in human glioblastoma cells. Tumour Biol. 2015, 36, 3823–3829.
  52. Su, C.; Shi, A.; Cao, G.; Tao, T.; Chen, R.; Hu, Z.; Shen, Z.; Tao, H.; Cao, B.; Hu, D.; et al. Fenofibrate suppressed proliferation and migration of human neuroblastoma cells via oxidative stress dependent of TXNIP upregulation. Biochem. Biophys. Res. Commun. 2015, 460, 983–988.
  53. Haynes, H.R.; Scott, H.L.; Killick-Cole, C.L.; Shaw, G.; Brend, T.; Hares, K.M.; Redondo, J.; Kemp, K.C.; Ballesteros, L.S.; Herman, A.; et al. shRNA-mediated PPARα knockdown in human glioma stem cells reduces in vitro proliferation and inhibits orthotopic xenograft tumour growth. J. Pathol. 2019, 247, 422–434.
  54. Chen, Y.; Wang, Y.; Huang, Y.; Zeng, H.; Hu, B.; Guan, L.; Zhang, H.; Yu, A.M.; Johnson, C.H.; Gonzalez, F.J.; et al. PPARα regulates tumor cell proliferation and senescence via a novel target gene carnitine palmitoyltransferase 1C. Carcinogenesis 2017, 38, 474–483.
  55. Stebbins, K.J.; Broadhead, A.R.; Cabrera, G.; Correa, L.D.; Messmer, D.; Bundey, R.; Baccei, C.; Bravo, Y.; Chen, A.; Stock, N.S.; et al. In vitro and in vivo pharmacology of NXT629, a novel and selective PPARα antagonist. Eur. J. Pharmacol. 2017, 809, 130–140.
  56. Li, M.Y.; Yuan, H.; Ma, L.T.; Kong, A.W.; Hsin, M.K.; Yip, J.H.; Underwood, M.J.; Chen, G.G. Roles of peroxisome proliferator-activated receptor-α and -γ in the development of non-small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 2010, 43, 674–683.
  57. Liang, H.; Kowalczyk, P.; Junco, J.J.; Klug-De Santiago, H.L.; Malik, G.; Wei, S.J.; Slaga, T.J. Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPARα receptors. Mol. Carcinog. 2014, 53, 753–763.
  58. Skrypnyk, N.; Chen, X.; Hu, W.; Su, Y.; Mont, S.; Yang, S.; Gangadhariah, M.; Wei, S.; Falck, J.R.; Jat, J.L.; et al. PPARα activation can help prevent and treat non-small cell lung cancer. Cancer Res. 2014, 74, 621–631.
  59. Pozzi, A.; Ibanez, M.R.; Gatica, A.E.; Yang, S.; Wei, S.; Mei, S.; Falck, J.R.; Capdevila, J.H. Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis. J. Biol. Chem. 2007, 282, 17685–17695.
  60. Huang, J.; Das, S.K.; Jha, P.; Al Zoughbi, W.; Schauer, S.; Claudel, T.; Sexl, V.; Vesely, P.; Birner-Gruenberger, R.; Kratky, D.; et al. The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochim. Biophys. Acta 2013, 1831, 1555–1565.
  61. Kong, R.; Wang, N.; Han, W.; Bao, W.; Lu, J. Fenofibrate Exerts Antitumor Effects in Colon Cancer via Regulation of DNMT1 and CDKN2A. PPAR Res. 2021, 2021, 6663782.
  62. Wagner, N.; Wagner, K.D. PPAR Beta/Delta and the Hallmarks of Cancer. Cells 2020, 9, 1133.
  63. Takayama, O.; Yamamoto, H.; Damdinsuren, B.; Sugita, Y.; Ngan, C.Y.; Xu, X.; Tsujino, T.; Takemasa, I.; Ikeda, M.; Sekimoto, M.; et al. Expression of PPARδ in multistage carcinogenesis of the colorectum: Implications of malignant cancer morphology. Br. J. Cancer 2006, 95, 889–895.
  64. Yoshinaga, M.; Taki, K.; Somada, S.; Sakiyama, Y.; Kubo, N.; Kaku, T.; Tsuruta, S.; Kusumoto, T.; Sakai, H.; Nakamura, K.; et al. The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig. Dis. Sci. 2011, 56, 1194–1200.
  65. Foreman, J.E.; Chang, W.C.; Palkar, P.S.; Zhu, B.; Borland, M.G.; Williams, J.L.; Kramer, L.R.; Clapper, M.L.; Gonzalez, F.J.; Peters, J.M. Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer. Mol. Carcinog. 2011, 50, 884–900.
  66. Wang, D.; Wang, H.; Guo, Y.; Ning, W.; Katkuri, S.; Wahli, W.; Desvergne, B.; Dey, S.K.; DuBois, R.N. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proc. Natl. Acad. Sci. USA 2006, 103, 19069–19074.
  67. Röhrl, C.; Kaindl, U.; Koneczny, I.; Hudec, X.; Baron, D.M.; König, J.S.; Marian, B. Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells. J. Cancer Res. Clin. Oncol. 2011, 137, 29–39.
  68. Zuo, X.; Peng, Z.; Moussalli, M.J.; Morris, J.S.; Broaddus, R.R.; Fischer, S.M.; Shureiqi, I. Targeted genetic disruption of peroxisome proliferator-activated receptor-δ and colonic tumorigenesis. J. Natl. Cancer Inst. 2009, 101, 762–767.
  69. Yang, L.; Zhou, J.; Ma, Q.; Wang, C.; Chen, K.; Meng, W.; Yu, Y.; Zhou, Z.; Sun, X. Knockdown of PPAR δ gene promotes the growth of colon cancer and reduces the sensitivity to bevacizumab in nude mice model. PLoS ONE 2013, 8, e60715.
  70. Gupta, R.A.; Wang, D.; Katkuri, S.; Wang, H.; Dey, S.K.; DuBois, R.N. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat. Med. 2004, 10, 245–247.
  71. Ding, J.; Gou, Q.; Jin, J.; Shi, J.; Liu, Q.; Hou, Y. Metformin inhibits PPARδ agonist-mediated tumor growth by reducing Glut1 and SLC1A5 expressions of cancer cells. Eur. J. Pharmacol. 2019, 857, 172425.
  72. Liu, Y.; Deguchi, Y.; Tian, R.; Wei, D.; Wu, L.; Chen, W.; Xu, W.; Xu, M.; Liu, F.; Gao, S.; et al. Pleiotropic Effects of PPARD Accelerate Colorectal Tumorigenesis, Progression, and Invasion. Cancer Res. 2019, 79, 954–969.
  73. Zuo, X.; Deguchi, Y.; Xu, W.; Liu, Y.; Li, H.S.; Wei, D.; Tian, R.; Chen, W.; Xu, M.; Yang, Y.; et al. PPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. Gastroenterology 2019, 157, 163–178.
  74. Zhou, D.; Jin, J.; Liu, Q.; Shi, J.; Hou, Y. PPARδ agonist enhances colitis-associated colorectal cancer. Eur. J. Pharmacol. 2019, 842, 248–254.
  75. Zuo, X.; Xu, M.; Yu, J.; Wu, Y.; Moussalli, M.J.; Manyam, G.C.; Lee, S.I.; Liang, S.; Gagea, M.; Morris, J.S.; et al. Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression. J. Natl. Cancer Inst. 2014, 106, dju052.
  76. Marin, H.E.; Peraza, M.A.; Billin, A.N.; Willson, T.M.; Ward, J.M.; Kennett, M.J.; Gonzalez, F.J.; Peters, J.M. Ligand activation of peroxisome proliferator-activated receptor β inhibits colon carcinogenesis. Cancer Res. 2006, 66, 4394–4401.
  77. Harman, F.S.; Nicol, C.J.; Marin, H.E.; Ward, J.M.; Gonzalez, F.J.; Peters, J.M. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat. Med. 2004, 10, 481–483.
  78. Beyaz, S.; Mana, M.D.; Roper, J.; Kedrin, D.; Saadatpour, A.; Hong, S.J.; Bauer-Rowe, K.E.; Xifaras, M.E.; Akkad, A.; Arias, E.; et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature 2016, 531, 53–58.
  79. Nagy, T.A.; Wroblewski, L.E.; Wang, D.; Piazuelo, M.B.; Delgado, A.; Romero-Gallo, J.; Noto, J.; Israel, D.A.; Ogden, S.R.; Correa, P.; et al. β-Catenin and p120 mediate PPARδ-dependent proliferation induced by Helicobacter pylori in human and rodent epithelia. Gastroenterology 2011, 141, 553–564.
  80. Girroir, E.E.; Hollingshead, H.E.; Billin, A.N.; Willson, T.M.; Robertson, G.P.; Sharma, A.K.; Amin, S.; Gonzalez, F.J.; Peters, J.M. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology 2008, 243, 236–243.
  81. Yao, P.L.; Morales, J.L.; Zhu, B.; Kang, B.H.; Gonzalez, F.J.; Peters, J.M. Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity. Mol. Cancer Ther. 2014, 13, 1008–1017.
  82. Yao, P.L.; Chen, L.; Dobrzański, T.P.; Zhu, B.; Kang, B.H.; Müller, R.; Gonzalez, F.J.; Peters, J.M. Peroxisome proliferator-activated receptor-β/δ inhibits human neuroblastoma cell tumorigenesis by inducing p53- and SOX2-mediated cell differentiation. Mol. Carcinog. 2017, 56, 1472–1483.
  83. Yao, P.L.; Chen, L.P.; Dobrzański, T.P.; Phillips, D.A.; Zhu, B.; Kang, B.H.; Gonzalez, F.J.; Peters, J.M. Inhibition of testicular embryonal carcinoma cell tumorigenicity by peroxisome proliferator-activated receptor-β/δ- and retinoic acid receptor-dependent mechanisms. Oncotarget 2015, 6, 36319–36337.
  84. Yuan, H.; Lu, J.; Xiao, J.; Upadhyay, G.; Umans, R.; Kallakury, B.; Yin, Y.; Fant, M.E.; Kopelovich, L.; Glazer, R.I. PPARδ induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation. Cancer Res. 2013, 73, 4349–4361.
  85. Pollock, C.B.; Yin, Y.; Yuan, H.; Zeng, X.; King, S.; Li, X.; Kopelovich, L.; Albanese, C.; Glazer, R.I. PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis. PLoS ONE 2011, 6, e16215.
  86. Yin, Y.; Russell, R.G.; Dettin, L.E.; Bai, R.; Wei, Z.L.; Kozikowski, A.P.; Kopelovich, L.; Kopleovich, L.; Glazer, R.I. Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 2005, 65, 3950–3957.
  87. Ghosh, M.; Ai, Y.; Narko, K.; Wang, Z.; Peters, J.M.; Hla, T. PPARδ is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins Other Lipid Mediat. 2009, 88, 97–100.
  88. Levi, L.; Lobo, G.; Doud, M.K.; von Lintig, J.; Seachrist, D.; Tochtrop, G.P.; Noy, N. Genetic ablation of the fatty acid-binding protein FABP5 suppresses HER2-induced mammary tumorigenesis. Cancer Res. 2013, 73, 4770–4780.
  89. Schug, T.T.; Berry, D.C.; Toshkov, I.A.; Cheng, L.; Nikitin, A.Y.; Noy, N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR. Proc. Natl. Acad. Sci. USA 2008, 105, 7546–7551.
  90. Morgan, E.; Kannan-Thulasiraman, P.; Noy, N. Involvement of Fatty Acid Binding Protein 5 and PPARβ/δ in Prostate Cancer Cell Growth. PPAR Res. 2010, 2010, 234629.
  91. Her, N.G.; Jeong, S.I.; Cho, K.; Ha, T.K.; Han, J.; Ko, K.P.; Park, S.K.; Lee, J.H.; Lee, M.G.; Ryu, B.K.; et al. PPARδ promotes oncogenic redirection of TGF-β1 signaling through the activation of the ABCA1-Cav1 pathway. Cell Cycle 2013, 12, 1521–1535.
  92. Martín-Martín, N.; Zabala-Letona, A.; Fernández-Ruiz, S.; Arreal, L.; Camacho, L.; Castillo-Martin, M.; Cortazar, A.R.; Torrano, V.; Astobiza, I.; Zúñiga-García, P.; et al. PPARδ Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. Cancer Res. 2018, 78, 399–409.
  93. Balandaram, G.; Kramer, L.R.; Kang, B.H.; Murray, I.A.; Perdew, G.H.; Gonzalez, F.J.; Peters, J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice. Toxicology 2016, 363–364, 1–9.
  94. Xu, L.; Han, C.; Lim, K.; Wu, T. Cross-talk between peroxisome proliferator-activated receptor δ and cytosolic phospholipase A(2)α/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res. 2006, 66, 11859–11868.
  95. Michiels, J.F.; Perrin, C.; Leccia, N.; Massi, D.; Grimaldi, P.; Wagner, N. PPARβ activation inhibits melanoma cell proliferation involving repression of the Wilms’ tumour suppressor WT1. Pflugers Arch. 2010, 459, 689–703.
  96. Wagner, N.; Panelos, J.; Massi, D.; Wagner, K.D. The Wilms’ tumor suppressor WT1 is associated with melanoma proliferation. Pflugers Arch. 2008, 455, 839–847.
  97. Kim, D.J.; Bility, M.T.; Billin, A.N.; Willson, T.M.; Gonzalez, F.J.; Peters, J.M. PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 2006, 13, 53–60.
  98. Borland, M.G.; Kehres, E.M.; Lee, C.; Wagner, A.L.; Shannon, B.E.; Albrecht, P.P.; Zhu, B.; Gonzalez, F.J.; Peters, J.M. Inhibition of tumorigenesis by peroxisome proliferator-activated receptor (PPAR)-dependent cell cycle blocks in human skin carcinoma cells. Toxicology 2018, 404–405, 25–32.
  99. Zhu, B.; Bai, R.; Kennett, M.J.; Kang, B.H.; Gonzalez, F.J.; Peters, J.M. Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase 2. Mol. Cancer Ther. 2010, 9, 3267–3277.
  100. Bility, M.T.; Zhu, B.; Kang, B.H.; Gonzalez, F.J.; Peters, J.M. Ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol. Sci. 2010, 113, 27–36.
  101. Kim, D.J.; Prabhu, K.S.; Gonzalez, F.J.; Peters, J.M. Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). Carcinogenesis 2006, 27, 1105–1112.
  102. Montagner, A.; Delgado, M.B.; Tallichet-Blanc, C.; Chan, J.S.; Sng, M.K.; Mottaz, H.; Degueurce, G.; Lippi, Y.; Moret, C.; Baruchet, M.; et al. Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer. EMBO Mol. Med. 2014, 6, 80–98.
  103. Tan, M.W.Y.; Sng, M.K.; Cheng, H.S.; Low, Z.S.; Leong, B.J.J.; Chua, D.; Tan, E.H.P.; Chan, J.S.K.; Yip, Y.S.; Lee, Y.H.; et al. Deficiency in fibroblast PPARβ/δ reduces nonmelanoma skin cancers in mice. Cell Death Differ. 2020, 27, 2668–2680.
  104. Pedchenko, T.V.; Gonzalez, A.L.; Wang, D.; DuBois, R.N.; Massion, P.P. Peroxisome proliferator—Activated receptor β/δ expression and activation in lung cancer. Am. J. Respir. Cell Mol. Biol. 2008, 39, 689–696.
  105. Genini, D.; Garcia-Escudero, R.; Carbone, G.M.; Catapano, C.V. Transcriptional and Non-Transcriptional Functions of PPARβ/δ in Non-Small Cell Lung Cancer. PLoS ONE 2012, 7, e46009.
  106. Sun, X.; Ritzenthaler, J.D.; Zhong, X.; Zheng, Y.; Roman, J.; Han, S. Nicotine stimulates PPARβ/δ expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2α. Cancer Res. 2009, 69, 6445–6453.
  107. He, P.; Borland, M.G.; Zhu, B.; Sharma, A.K.; Amin, S.; El-Bayoumy, K.; Gonzalez, F.J.; Peters, J.M. Effect of ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in human lung cancer cell lines. Toxicology 2008, 254, 112–117.
  108. Müller-Brüsselbach, S.; Ebrahimsade, S.; Jäkel, J.; Eckhardt, J.; Rapp, U.R.; Peters, J.M.; Moll, R.; Müller, R. Growth of transgenic RAF-induced lung adenomas is increased in mice with a disrupted PPARβ/δ gene. Int. J. Oncol. 2007, 31, 607–611.
  109. Gu, L.; Shi, Y.; Xu, W.; Ji, Y. PPARβ/δ Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by Regulating miR-206. Oncol. Res. 2019, 27, 923–933.
  110. Wagner, K.D.; Benchetrit, M.; Bianchini, L.; Michiels, J.F.; Wagner, N. Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferation. J. Pathol. 2011, 224, 575–588.
  111. Zeng, L.; Geng, Y.; Tretiakova, M.; Yu, X.; Sicinski, P.; Kroll, T.G. Peroxisome proliferator-activated receptor-δ induces cell proliferation by a cyclin E1-dependent mechanism and is up-regulated in thyroid tumors. Cancer Res. 2008, 68, 6578–6586.
  112. Daikoku, T.; Tranguch, S.; Chakrabarty, A.; Wang, D.; Khabele, D.; Orsulic, S.; Morrow, J.D.; Dubois, R.N.; Dey, S.K. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-δ signaling in epithelial ovarian cancer. Cancer Res. 2007, 67, 5285–5292.
  113. Li, Y.J.; Sun, L.; Shi, Y.; Wang, G.; Wang, X.; Dunn, S.E.; Iorio, C.; Screaton, R.A.; Spaner, D.E. PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions. Leukemia 2017, 31, 1905–1914.
  114. Sun, L.; Shi, Y.; Wang, G.; Wang, X.; Zeng, S.; Dunn, S.E.; Fairn, G.D.; Li, Y.J.; Spaner, D.E. PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells. Leukemia 2018, 32, 184–193.
  115. Lefebvre, A.M.; Chen, I.; Desreumaux, P.; Najib, J.; Fruchart, J.C.; Geboes, K.; Briggs, M.; Heyman, R.; Auwerx, J. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 1998, 4, 1053–1057.
  116. Saez, E.; Tontonoz, P.; Nelson, M.C.; Alvarez, J.G.; Ming, U.T.; Baird, S.M.; Thomazy, V.A.; Evans, R.M. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat. Med. 1998, 4, 1058–1061.
  117. Brockman, J.A.; Gupta, R.A.; Dubois, R.N. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998, 115, 1049–1055.
  118. Sarraf, P.; Mueller, E.; Jones, D.; King, F.J.; DeAngelo, D.J.; Partridge, J.B.; Holden, S.A.; Chen, L.B.; Singer, S.; Fletcher, C.; et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 1998, 4, 1046–1052.
  119. Kitamura, S.; Miyazaki, Y.; Shinomura, Y.; Kondo, S.; Kanayama, S.; Matsuzawa, Y. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res. 1999, 90, 75–80.
  120. Chintharlapalli, S.; Papineni, S.; Safe, S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARγ-dependent and PPARγ-independent pathways. Mol. Cancer Ther. 2006, 5, 1362–1370.
  121. Kubota, T.; Koshizuka, K.; Williamson, E.A.; Asou, H.; Said, J.W.; Holden, S.; Miyoshi, I.; Koeffler, H.P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998, 58, 3344–3352.
  122. Shappell, S.B.; Gupta, R.A.; Manning, S.; Whitehead, R.; Boeglin, W.E.; Schneider, C.; Case, T.; Price, J.; Jack, G.S.; Wheeler, T.M.; et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001, 61, 497–503.
  123. Yoshimura, R.; Matsuyama, M.; Hase, T.; Tsuchida, K.; Kuratsukuri, K.; Kawahito, Y.; Sano, H.; Segawa, Y.; Nakatani, T. The effect of peroxisome proliferator-activated receptor-γ ligand on urological cancer cells. Int. J. Mol. Med. 2003, 12, 861–865.
  124. Tontonoz, P.; Singer, S.; Forman, B.M.; Sarraf, P.; Fletcher, J.A.; Fletcher, C.D.; Brun, R.P.; Mueller, E.; Altiok, S.; Oppenheim, H.; et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 1997, 94, 237–241.
  125. Takahashi, N.; Okumura, T.; Motomura, W.; Fujimoto, Y.; Kawabata, I.; Kohgo, Y. Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 1999, 455, 135–139.
  126. Sato, H.; Ishihara, S.; Kawashima, K.; Moriyama, N.; Suetsugu, H.; Kazumori, H.; Okuyama, T.; Rumi, M.A.; Fukuda, R.; Nagasue, N.; et al. Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists. Br. J. Cancer 2000, 83, 1394–1400.
  127. Kassouf, W.; Chintharlapalli, S.; Abdelrahim, M.; Nelkin, G.; Safe, S.; Kamat, A.M. Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes: A new class of peroxisome proliferator-activated receptor γ agonists. Cancer Res. 2006, 66, 412–418.
  128. Han, S.W.; Greene, M.E.; Pitts, J.; Wada, R.K.; Sidell, N. Novel expression and function of peroxisome proliferator-activated receptor γ (PPARγ) in human neuroblastoma cells. Clin. Cancer Res. 2001, 7, 98–104.
  129. Cellai, I.; Benvenuti, S.; Luciani, P.; Galli, A.; Ceni, E.; Simi, L.; Baglioni, S.; Muratori, M.; Ottanelli, B.; Serio, M.; et al. Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells. Br. J. Cancer 2006, 95, 879–888.
  130. Chearwae, W.; Bright, J.J. PPARγ agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br. J. Cancer 2008, 99, 2044–2053.
  131. Wang, P.; Yu, J.; Yin, Q.; Li, W.; Ren, X.; Hao, X. Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-delta mediated pathway. Neurochem. Res. 2012, 37, 2076–2084.
  132. Jozkowicz, A.; Dulak, J.; Piatkowska, E.; Placha, W.; Dembinska-Kiec, A. Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim. Pol. 2000, 47, 1147–1157.
  133. Freudlsperger, C.; Moll, I.; Schumacher, U.; Thies, A. Anti-proliferative effect of peroxisome proliferator-activated receptor γ agonists on human malignant melanoma cells in vitro. Anticancer Drugs 2006, 17, 325–332.
  134. Botton, T.; Puissant, A.; Bahadoran, P.; Annicotte, J.S.; Fajas, L.; Ortonne, J.P.; Gozzerino, G.; Zamoum, T.; Tartare-Deckert, S.; Bertolotto, C.; et al. In vitro and in vivo anti-melanoma effects of ciglitazone. J. Investig. Dermatol. 2009, 129, 1208–1218.
  135. Placha, W.; Gil, D.; Dembińska-Kieć, A.; Laidler, P. The effect of PPARγ ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res. 2003, 13, 447–456.
  136. Keshamouni, V.G.; Reddy, R.C.; Arenberg, D.A.; Joel, B.; Thannickal, V.J.; Kalemkerian, G.P.; Standiford, T.J. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004, 23, 100–108.
  137. Han, S.; Roman, J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways. Mol. Cancer Ther. 2006, 5, 430–437.
  138. Ferruzzi, P.; Ceni, E.; Tarocchi, M.; Grappone, C.; Milani, S.; Galli, A.; Fiorelli, G.; Serio, M.; Mannelli, M. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J. Clin. Endocrinol. Metab. 2005, 90, 1332–1339.
  139. Betz, M.J.; Shapiro, I.; Fassnacht, M.; Hahner, S.; Reincke, M.; Beuschlein, F.; Network, G.a.A.A. Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J. Clin. Endocrinol. Metab. 2005, 90, 3886–3896.
  140. Yu, J.; Qiao, L.; Zimmermann, L.; Ebert, M.P.; Zhang, H.; Lin, W.; Röcken, C.; Malfertheiner, P.; Farrell, G.C. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006, 43, 134–143.
  141. Ota, K.; Ito, K.; Suzuki, T.; Saito, S.; Tamura, M.; Hayashi, S.; Okamura, K.; Sasano, H.; Yaegashi, N. Peroxisome proliferator-activated receptor γ and growth inhibition by its ligands in uterine endometrial carcinoma. Clin. Cancer Res. 2006, 12, 4200–4208.
  142. Lei, P.; Abdelrahim, M.; Safe, S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit ovarian cancer cell growth through peroxisome proliferator-activated receptor-dependent and independent pathways. Mol. Cancer Ther. 2006, 5, 2324–2336.
  143. Vignati, S.; Albertini, V.; Rinaldi, A.; Kwee, I.; Riva, C.; Oldrini, R.; Capella, C.; Bertoni, F.; Carbone, G.M.; Catapano, C.V. Cellular and molecular consequences of peroxisome proliferator-activated receptor-γ activation in ovarian cancer cells. Neoplasia 2006, 8, 851–861.
  144. Garcia-Bates, T.M.; Bernstein, S.H.; Phipps, R.P. Peroxisome proliferator-activated receptor γ overexpression suppresses growth and induces apoptosis in human multiple myeloma cells. Clin. Cancer Res. 2008, 14, 6414–6425.
  145. Garcia-Bates, T.M.; Peslak, S.A.; Baglole, C.J.; Maggirwar, S.B.; Bernstein, S.H.; Phipps, R.P. Peroxisome proliferator-activated receptor gamma overexpression and knockdown: Impact on human B cell lymphoma proliferation and survival. Cancer Immunol. Immunother. 2009, 58, 1071–1083.
  146. Hamaguchi, N.; Hamada, H.; Miyoshi, S.; Irifune, K.; Ito, R.; Miyazaki, T.; Higaki, J. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth. Cancer Sci. 2010, 101, 1955–1964.
  147. Sawayama, H.; Ishimoto, T.; Watanabe, M.; Yoshida, N.; Sugihara, H.; Kurashige, J.; Hirashima, K.; Iwatsuki, M.; Baba, Y.; Oki, E.; et al. Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer. Cancer Res. 2014, 74, 575–585.
  148. Prost, S.; Relouzat, F.; Spentchian, M.; Ouzegdouh, Y.; Saliba, J.; Massonnet, G.; Beressi, J.P.; Verhoeyen, E.; Raggueneau, V.; Maneglier, B.; et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature 2015, 525, 380–383.
  149. Rousselot, P.; Prost, S.; Guilhot, J.; Roy, L.; Etienne, G.; Legros, L.; Charbonnier, A.; Coiteux, V.; Cony-Makhoul, P.; Huguet, F.; et al. Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study. Cancer 2017, 123, 1791–1799.
  150. Kato, Y.; Ying, H.; Zhao, L.; Furuya, F.; Araki, O.; Willingham, M.C.; Cheng, S.Y. PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway. Oncogene 2006, 25, 2736–2747.
  151. Wu, L.; Yan, C.; Czader, M.; Foreman, O.; Blum, J.S.; Kapur, R.; Du, H. Inhibition of PPARγ in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 2012, 119, 115–126.
  152. Pignatelli, M.; Cortés-Canteli, M.; Lai, C.; Santos, A.; Perez-Castillo, A. The peroxisome proliferator-activated receptor γ is an inhibitor of ErbBs activity in human breast cancer cells. J. Cell Sci. 2001, 114, 4117–4126.
  153. Qin, C.; Burghardt, R.; Smith, R.; Wormke, M.; Stewart, J.; Safe, S. Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res. 2003, 63, 958–964.
  154. Houston, K.D.; Copland, J.A.; Broaddus, R.R.; Gottardis, M.M.; Fischer, S.M.; Walker, C.L. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor γ ligands in uterine leiomyoma. Cancer Res. 2003, 63, 1221–1227.
  155. Catalano, S.; Mauro, L.; Bonofiglio, D.; Pellegrino, M.; Qi, H.; Rizza, P.; Vizza, D.; Bossi, G.; Andò, S. In vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancer. Am. J. Pathol. 2011, 179, 1030–1040.
  156. Kim, H.J.; Kim, J.Y.; Meng, Z.; Wang, L.H.; Liu, F.; Conrads, T.P.; Burke, T.R.; Veenstra, T.D.; Farrar, W.L. 15-deoxy-Δ12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-α via covalent modification of DNA-binding domain. Cancer Res. 2007, 67, 2595–2602.
  157. Vanderlaag, K.; Su, Y.; Frankel, A.E.; Grage, H.; Smith, R.; Khan, S.; Safe, S. 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer Res. Treat. 2008, 109, 273–283.
  158. Saez, E.; Rosenfeld, J.; Livolsi, A.; Olson, P.; Lombardo, E.; Nelson, M.; Banayo, E.; Cardiff, R.D.; Izpisua-Belmonte, J.C.; Evans, R.M. PPAR γ signaling exacerbates mammary gland tumor development. Genes Dev. 2004, 18, 528–540.
  159. Avena, P.; Anselmo, W.; Whitaker-Menezes, D.; Wang, C.; Pestell, R.G.; Lamb, R.S.; Hulit, J.; Casaburi, I.; Andò, S.; Martinez-Outschoorn, U.E.; et al. Compartment-specific activation of PPARγ governs breast cancer tumor growth, via metabolic reprogramming and symbiosis. Cell Cycle 2013, 12, 1360–1370.
  160. Apostoli, A.J.; Skelhorne-Gross, G.E.; Rubino, R.E.; Peterson, N.T.; Di Lena, M.A.; Schneider, M.M.; SenGupta, S.K.; Nicol, C.J. Loss of PPARγ expression in mammary secretory epithelial cells creates a pro-breast tumorigenic environment. Int. J. Cancer 2014, 134, 1055–1066.
  161. Yee, L.D.; Williams, N.; Wen, P.; Young, D.C.; Lester, J.; Johnson, M.V.; Farrar, W.B.; Walker, M.J.; Povoski, S.P.; Suster, S.; et al. Pilot study of rosiglitazone therapy in women with breast cancer: Effects of short-term therapy on tumor tissue and serum markers. Clin. Cancer Res. 2007, 13, 246–252.
  162. He, G.; Muga, S.; Thuillier, P.; Lubet, R.A.; Fischer, S.M. The effect of PPARγ ligands on UV- or chemically-induced carcinogenesis in mouse skin. Mol. Carcinog. 2005, 43, 198–206.
  163. Palakurthi, S.S.; Aktas, H.; Grubissich, L.M.; Mortensen, R.M.; Halperin, J.A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res. 2001, 61, 6213–6218.
  164. Lucarelli, E.; Sangiorgi, L.; Maini, V.; Lattanzi, G.; Marmiroli, S.; Reggiani, M.; Mordenti, M.; Alessandra Gobbi, G.; Scrimieri, F.; Zambon Bertoja, A.; et al. Troglitazione affects survival of human osteosarcoma cells. Int. J. Cancer 2002, 98, 344–351.
  165. Haydon, R.C.; Zhou, L.; Feng, T.; Breyer, B.; Cheng, H.; Jiang, W.; Ishikawa, A.; Peabody, T.; Montag, A.; Simon, M.A.; et al. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin. Cancer Res. 2002, 8, 1288–1294.
  166. Srivastava, N.; Kollipara, R.K.; Singh, D.K.; Sudderth, J.; Hu, Z.; Nguyen, H.; Wang, S.; Humphries, C.G.; Carstens, R.; Huffman, K.E.; et al. Inhibition of cancer cell proliferation by PPARγ is mediated by a metabolic switch that increases reactive oxygen species levels. Cell Metab. 2014, 20, 650–661.
  167. Musicant, A.M.; Parag-Sharma, K.; Gong, W.; Sengupta, M.; Chatterjee, A.; Henry, E.C.; Tsai, Y.H.; Hayward, M.C.; Sheth, S.; Betancourt, R.; et al. CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition. Cell Rep. 2021, 34, 108768.
  168. Pishvaian, M.J.; Marshall, J.L.; Wagner, A.J.; Hwang, J.J.; Malik, S.; Cotarla, I.; Deeken, J.F.; He, A.R.; Daniel, H.; Halim, A.B.; et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 2012, 118, 5403–5413.
  169. Demetri, G.D.; Fletcher, C.D.; Mueller, E.; Sarraf, P.; Naujoks, R.; Campbell, N.; Spiegelman, B.M.; Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA 1999, 96, 3951–3956.
  170. Wagner, N.; Wagner, K.D. PPARs and Angiogenesis-Implications in Pathology. Int. J. Mol. Sci. 2020, 21, 5723.
  171. Jiao, H.L.; Zhao, B.L. Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms. Toxicol. Appl. Pharmacol. 2002, 185, 172–179.
  172. Gao, J.; Liu, Q.; Xu, Y.; Gong, X.; Zhang, R.; Zhou, C.; Su, Z.; Jin, J.; Shi, H.; Shi, J.; et al. PPARα induces cell apoptosis by destructing Bcl2. Oncotarget 2015, 6, 44635–44642.
  173. Holland, C.M.; Saidi, S.A.; Evans, A.L.; Sharkey, A.M.; Latimer, J.A.; Crawford, R.A.; Charnock-Jones, D.S.; Print, C.G.; Smith, S.K. Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets. Mol. Cancer Ther. 2004, 3, 993–1001.
  174. Crowe, D.L.; Chandraratna, R.A. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 2004, 6, R546–R555.
  175. Strakova, N.; Ehrmann, J.; Bartos, J.; Malikova, J.; Dolezel, J.; Kolar, Z. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 2005, 52, 126–136.
  176. Martinasso, G.; Oraldi, M.; Trombetta, A.; Maggiora, M.; Bertetto, O.; Canuto, R.A.; Muzio, G. Involvement of PPARs in Cell Proliferation and Apoptosis in Human Colon Cancer Specimens and in Normal and Cancer Cell Lines. PPAR Res. 2007, 2007, 93416.
  177. Xue, J.; Zhu, W.; Song, J.; Jiao, Y.; Luo, J.; Yu, C.; Zhou, J.; Wu, J.; Chen, M.; Ding, W.Q.; et al. Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway. Oncogene 2018, 37, 953–962.
  178. Wang, M.S.; Han, Q.S.; Jia, Z.R.; Chen, C.S.; Qiao, C.; Liu, Q.Q.; Zhang, Y.M.; Wang, K.W.; Wang, J.; Xiao, K.; et al. PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway. Acta Pharmacol. Sin. 2022, 43, 167–176.
  179. Maggiora, M.; Bologna, M.; Cerù, M.P.; Possati, L.; Angelucci, A.; Cimini, A.; Miglietta, A.; Bozzo, F.; Margiotta, C.; Muzio, G.; et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int. J. Cancer 2004, 112, 909–919.
  180. Tuller, E.R.; Brock, A.L.; Yu, H.; Lou, J.R.; Benbrook, D.M.; Ding, W.Q. PPARα signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochem. Pharmacol. 2009, 77, 1480–1486.
  181. Zang, C.; Liu, H.; Bertz, J.; Possinger, K.; Koeffler, H.P.; Elstner, E.; Eucker, J. Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor α/γ, in human breast cancer cells. Mol. Cancer Ther. 2009, 8, 2296–2307.
  182. Ma, Y.; Wang, B.; Li, L.; Wang, F.; Xia, X. The administration of peroxisome proliferator-activated receptors α/γ agonist TZD18 inhibits cell growth and induces apoptosis in human gastric cancer cell lines. J. Cancer Res. Ther. 2019, 15, 120–125.
  183. Zak, Z.; Gelebart, P.; Lai, R. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFα/NF-κB signaling axis. Leukemia 2010, 24, 1476–1486.
  184. Deepa, P.R.; Vandhana, S.; Krishnakumar, S. Fatty acid synthase inhibition induces differential expression of genes involved in apoptosis and cell proliferation in ocular cancer cells. Nutr. Cancer 2013, 65, 311–316.
  185. Casella, M.L.; Parody, J.P.; Ceballos, M.P.; Quiroga, A.D.; Ronco, M.T.; Francés, D.E.; Monti, J.A.; Pisani, G.B.; Carnovale, C.E.; Carrillo, M.C.; et al. Quercetin prevents liver carcinogenesis by inducing cell cycle arrest, decreasing cell proliferation and enhancing apoptosis. Mol. Nutr. Food Res. 2014, 58, 289–300.
  186. Abu Aboud, O.; Wettersten, H.I.; Weiss, R.H. Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS ONE 2013, 8, e71115.
  187. Abu Aboud, O.; Donohoe, D.; Bultman, S.; Fitch, M.; Riiff, T.; Hellerstein, M.; Weiss, R.H. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am. J. Physiol. Cell Physiol. 2015, 308, C890–C898.
  188. Florio, R.; De Lellis, L.; di Giacomo, V.; Di Marcantonio, M.C.; Cristiano, L.; Basile, M.; Verginelli, F.; Verzilli, D.; Ammazzalorso, A.; Prasad, S.C.; et al. Effects of PPARα inhibition in head and neck paraganglioma cells. PLoS ONE 2017, 12, e0178995.
  189. He, T.C.; Chan, T.A.; Vogelstein, B.; Kinzler, K.W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99, 335–345.
  190. Wang, D.; Wang, H.; Shi, Q.; Katkuri, S.; Walhi, W.; Desvergne, B.; Das, S.K.; Dey, S.K.; DuBois, R.N. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell 2004, 6, 285–295.
  191. Cutler, N.S.; Graves-Deal, R.; LaFleur, B.J.; Gao, Z.; Boman, B.M.; Whitehead, R.H.; Terry, E.; Morrow, J.D.; Coffey, R.J. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res. 2003, 63, 1748–1751.
  192. Liou, J.Y.; Lee, S.; Ghelani, D.; Matijevic-Aleksic, N.; Wu, K.K. Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated 14-3-3 upregulation. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1481–1487.
  193. Wang, D.; Ning, W.; Xie, D.; Guo, L.; DuBois, R.N. Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells. Oncogene 2012, 31, 1013–1023.
  194. Bell, E.; Ponthan, F.; Whitworth, C.; Westermann, F.; Thomas, H.; Redfern, C.P. Cell survival signalling through PPARδ and arachidonic acid metabolites in neuroblastoma. PLoS ONE 2013, 8, e68859.
  195. Tong-Lin Wu, T.; Tong, Y.C.; Chen, I.H.; Niu, H.S.; Li, Y.; Cheng, J.T. Induction of apoptosis in prostate cancer by ginsenoside Rh2. Oncotarget 2018, 9, 11109–11118.
  196. Wu, T.T.; Niu, H.S.; Chen, L.J.; Cheng, J.T.; Tong, Y.C. Increase of human prostate cancer cell (DU145) apoptosis by telmisartan through PPAR-delta pathway. Eur. J. Pharmacol. 2016, 775, 35–42.
  197. Péchery, A.; Fauconnet, S.; Bittard, H.; Lascombe, I. Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells. Tumour Biol. 2016, 37, 14789–14802.
  198. Shen, B.; Li, A.; Wan, Y.Y.; Shen, G.; Zhu, J.; Nie, Y. Lack of PPAR. Biomed Res. Int. 2020, 2020, 9563851.
  199. Padilla, J.; Kaur, K.; Harris, S.G.; Phipps, R.P. PPAR-γ-mediated regulation of normal and malignant B lineage cells. Ann. N. Y. Acad. Sci. 2000, 905, 97–109.
  200. Padilla, J.; Kaur, K.; Cao, H.J.; Smith, T.J.; Phipps, R.P. Peroxisome proliferator activator receptor-γ agonists and 15-deoxy-Δ12,1412,14-PGJ2 induce apoptosis in normal and malignant B-lineage cells. J. Immunol. 2000, 165, 6941–6948.
  201. Piva, R.; Gianferretti, P.; Ciucci, A.; Taulli, R.; Belardo, G.; Santoro, M.G. 15-Deoxy-Δ12,14-prostaglandin J2 induces apoptosis in human malignant B cells: An effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins. Blood 2005, 105, 1750–1758.
  202. Tsao, T.; Kornblau, S.; Safe, S.; Watt, J.C.; Ruvolo, V.; Chen, W.; Qiu, Y.; Coombes, K.R.; Ju, Z.; Abdelrahim, M.; et al. Role of peroxisome proliferator-activated receptor-γ and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res. 2010, 70, 4949–4960.
  203. Clay, C.E.; Monjazeb, A.; Thorburn, J.; Chilton, F.H.; High, K.P. 15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. J. Lipid Res. 2002, 43, 1818–1828.
  204. Chaffer, C.L.; Thomas, D.M.; Thompson, E.W.; Williams, E.D. PPARγ-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006, 6, 53.
  205. Kondoh, K.; Tsuji, N.; Asanuma, K.; Kobayashi, D.; Watanabe, N. Inhibition of estrogen receptor β-mediated human telomerase reverse transcriptase gene transcription via the suppression of mitogen-activated protein kinase signaling plays an important role in 15-deoxy-Δ12,14-prostaglandin J2-induced apoptosis in cancer cells. Exp. Cell Res. 2007, 313, 3486–3496.
  206. Lu, M.; Kwan, T.; Yu, C.; Chen, F.; Freedman, B.; Schafer, J.M.; Lee, E.J.; Jameson, J.L.; Jordan, V.C.; Cryns, V.L. Peroxisome proliferator-activated receptor γ agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J. Biol. Chem. 2005, 280, 6742–6751.
  207. Bräutigam, K.; Biernath-Wüpping, J.; Bauerschlag, D.O.; von Kaisenberg, C.S.; Jonat, W.; Maass, N.; Arnold, N.; Meinhold-Heerlein, I. Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines. J. Cancer Res. Clin. Oncol. 2011, 137, 875–886.
  208. Bonofiglio, D.; Cione, E.; Qi, H.; Pingitore, A.; Perri, M.; Catalano, S.; Vizza, D.; Panno, M.L.; Genchi, G.; Fuqua, S.A.; et al. Combined low doses of PPARγ and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am. J. Pathol. 2009, 175, 1270–1280.
  209. Kazberuk, A.; Chalecka, M.; Palka, J.; Surazynski, A. Nonsteroidal Anti-Inflammatory Drugs as PPARγ Agonists Can Induce PRODH/POX-Dependent Apoptosis in Breast Cancer Cells: New Alternative Pathway in NSAID-Induced Apoptosis. Int. J. Mol. Sci. 2022, 23, 1510.
  210. Guan, Y.F.; Zhang, Y.H.; Breyer, R.M.; Davis, L.; Breyer, M.D. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999, 1, 330–339.
  211. Lu, J.; Imamura, K.; Nomura, S.; Mafune, K.; Nakajima, A.; Kadowaki, T.; Kubota, N.; Terauchi, Y.; Ishii, G.; Ochiai, A.; et al. Chemopreventive effect of peroxisome proliferator-activated receptor γ on gastric carcinogenesis in mice. Cancer Res. 2005, 65, 4769–4774.
  212. Tsubouchi, Y.; Sano, H.; Kawahito, Y.; Mukai, S.; Yamada, R.; Kohno, M.; Inoue, K.; Hla, T.; Kondo, M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem. Biophys. Res. Commun. 2000, 270, 400–405.
  213. Takashima, T.; Fujiwara, Y.; Higuchi, K.; Arakawa, T.; Yano, Y.; Hasuma, T.; Otani, S. PPAR-γ ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int. J. Oncol. 2001, 19, 465–471.
  214. Eibl, G.; Wente, M.N.; Reber, H.A.; Hines, O.J. Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis. Biochem. Biophys. Res. Commun. 2001, 287, 522–529.
  215. Li, M.Y.; Deng, H.; Zhao, J.M.; Dai, D.; Tan, X.Y. PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J. Gastroenterol. 2003, 9, 1220–1226.
  216. Kim, E.J.; Park, K.S.; Chung, S.Y.; Sheen, Y.Y.; Moon, D.C.; Song, Y.S.; Kim, K.S.; Song, S.; Yun, Y.P.; Lee, M.K.; et al. Peroxisome proliferator-activated receptor-γ activator 15-deoxy-Δ12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: Association with extracellular signal-regulated kinase signal pathway. J. Pharmacol. Exp. Ther. 2003, 307, 505–517.
  217. Strakova, N.; Ehrmann, J.; Dzubak, P.; Bouchal, J.; Kolar, Z. The synthetic ligand of peroxisome proliferator-activated receptor-γ ciglitazone affects human glioblastoma cell lines. J. Pharmacol. Exp. Ther. 2004, 309, 1239–1247.
  218. Konopleva, M.; Elstner, E.; McQueen, T.J.; Tsao, T.; Sudarikov, A.; Hu, W.; Schober, W.D.; Wang, R.Y.; Chism, D.; Kornblau, S.M.; et al. Peroxisome proliferator-activated receptor γ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol. Cancer Ther. 2004, 3, 1249–1262.
  219. Nam, D.H.; Ramachandran, S.; Song, D.K.; Kwon, K.Y.; Jeon, D.S.; Shin, S.J.; Kwon, S.H.; Cha, S.D.; Bae, I.; Cho, C.H. Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone. Mol. Hum. Reprod. 2007, 13, 829–836.
  220. Shimada, T.; Kojima, K.; Yoshiura, K.; Hiraishi, H.; Terano, A. Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 2002, 50, 658–664.
  221. Hernandez-Quiles, M.; Broekema, M.F.; Kalkhoven, E. PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action. Front. Endocrinol. 2021, 12, 624112.
  222. Kim, H.J.; Hwang, J.Y.; Choi, W.S.; Lee, J.H.; Chang, K.C.; Nishinaka, T.; Yabe-Nishimura, C.; Seo, H.G. Expression of a peroxisome proliferator-activated receptor γ 1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress. Clin. Cancer Res. 2007, 13, 2577–2583.
  223. Sun, H.; Berquin, I.M.; Owens, R.T.; O’Flaherty, J.T.; Edwards, I.J. Peroxisome proliferator-activated receptor γ-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res. 2008, 68, 2912–2919.
  224. Baek, S.J.; Wilson, L.C.; Hsi, L.C.; Eling, T.E. Troglitazone, a peroxisome proliferator-activated receptor γ (PPAR γ) ligand, selectively induces the early growth response-1 gene independently of PPAR γ. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 2003, 278, 5845–5853.
  225. Funao, K.; Matsuyama, M.; Kawahito, Y.; Sano, H.; Chargui, J.; Touraine, J.L.; Nakatani, T.; Yoshimura, R. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol. Rep. 2008, 20, 295–300.
  226. Funao, K.; Matsuyama, M.; Kawahito, Y.; Sano, H.; Chargui, J.; Touraine, J.L.; Nakatani, T.; Yoshimura, R. Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma. Mol. Med. Rep. 2009, 2, 193–198.
  227. Matsuyama, M.; Funao, K.; Kuratsukuri, K.; Tanaka, T.; Kawahito, Y.; Sano, H.; Chargui, J.; Touraine, J.L.; Yoshimura, N.; Yoshimura, R. Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp. Ther. Med. 2010, 1, 301–306.
  228. Zaytseva, Y.Y.; Wang, X.; Southard, R.C.; Wallis, N.K.; Kilgore, M.W. Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells. Mol. Cancer 2008, 7, 90.
  229. Khandekar, M.J.; Banks, A.S.; Laznik-Bogoslavski, D.; White, J.P.; Choi, J.H.; Kazak, L.; Lo, J.C.; Cohen, P.; Wong, K.K.; Kamenecka, T.M.; et al. Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. Proc. Natl. Acad. Sci. USA 2018, 115, 561–566.
  230. Schaefer, K.L.; Wada, K.; Takahashi, H.; Matsuhashi, N.; Ohnishi, S.; Wolfe, M.M.; Turner, J.R.; Nakajima, A.; Borkan, S.C.; Saubermann, L.J. Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 2005, 65, 2251–2259.
  231. Masuda, T.; Wada, K.; Nakajima, A.; Okura, M.; Kudo, C.; Kadowaki, T.; Kogo, M.; Kamisaki, Y. Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma. Clin. Cancer Res. 2005, 11, 4012–4021.
  232. Cerquetti, L.; Sampaoli, C.; Amendola, D.; Bucci, B.; Masuelli, L.; Marchese, R.; Misiti, S.; De Venanzi, A.; Poggi, M.; Toscano, V.; et al. Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Exp. Cell Res. 2011, 317, 1397–1410.
  233. Rovito, D.; Giordano, C.; Vizza, D.; Plastina, P.; Barone, I.; Casaburi, I.; Lanzino, M.; De Amicis, F.; Sisci, D.; Mauro, L.; et al. Omega-3 PUFA ethanolamides DHEA and EPEA induce autophagy through PPARγ activation in MCF-7 breast cancer cells. J. Cell. Physiol. 2013, 228, 1314–1322.
  234. To, K.K.W.; Wu, W.K.K.; Loong, H.H.F. PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy. Eur. J. Pharmacol. 2018, 823, 19–26.
  235. Yun, C.W.; Lee, S.H. The Roles of Autophagy in Cancer. Int. J. Mol. Sci. 2018, 19, 3466.
  236. Baron, D.M.; Kaindl, U.; Haudek-Prinz, V.J.; Bayer, E.; Röhrl, C.; Gerner, C.; Marian, B. Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone. PLoS ONE 2014, 9, e114158.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pathology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Nicole Wagner
,
Kay-Dietrich Wagner
View Times: 570
Revisions: 3 times (View History)
Update Date: 12 Aug 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback